Last reviewed · How we verify
Klebsiella Joint Infection — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Fortaz | CEFTAZIDIME | Pai Holdings Pharm | ceftazidime | 1985-01-01 | ||
| Rocephin | ceftriaxone | Generic (originally Roche) | Cephalosporin antibiotic (third-generation) | Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A | 1984-12-21 | |
| Ceftriaxon | Ceftriaxon | Centre Hospitalier Universitaire Vaudois | Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A | |||
| Ceftazidim | Ceftazidim | Tel-Aviv Sourasky Medical Center | Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pai Holdings Pharm · 2 drugs in Klebsiella Joint Infection
- Centre Hospitalier Universitaire Vaudois · 1 drug in Klebsiella Joint Infection
- Generic (originally Roche) · 1 drug in Klebsiella Joint Infection
- Tel-Aviv Sourasky Medical Center · 1 drug in Klebsiella Joint Infection
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Klebsiella Joint Infection:
- Klebsiella Joint Infection treatment updates — RSS
- Klebsiella Joint Infection treatment updates — Atom
- Klebsiella Joint Infection treatment updates — JSON
Cite this brief
Drug Landscape (2026). Klebsiella Joint Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/klebsiella-joint-infection. Accessed 2026-06-10.
Related
- Klebsiella Joint Infection full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing